Stock Taper
DMAAR
DRUGS MADE IN AMERICA ACQUISITION CORP. RIGHTS
NASDAQ
$0.13
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$285.28 M
52w High$0.13
52w Low$0.11
Dividend Yield
Frequency
P/E
Volume386
Shares Out.20.40M

COMPANY

LEADERSHIP

Roger Bendelac
CHIEF EXECUTIVE
Roger Bendelac

ABOUT

SECTOR
Financial Services
WENT PUBLIC
January 13, 2026
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
2

PRICE

$0.13 ▲ UP 0.00% (+$0.00)
$0.11$0.12$0.1310:14 AM10:23 AM10:33 AM10:42 AM10:51 AM11:01 AM11:10 AM0.13

About Drugs Made In America Acquisition Corp. Rights

https://dmaacorp.com ↗

Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.

INDUSTRY

Shell Companies

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets4
Debt To Equity1
Price To Earnings4
Price To Book1
Overall Score2

SECTORS PEERS

PEERPRICE
VNME$10.27COMPARE
EGHA$10.40COMPARE
QUMS$10.33COMPARE
LCCC$10.63COMPARE
SCAG$0.24COMPARE
TAVIR$0.09COMPARE